Illumina Beats Q2 Estimates, Raises Full-Year Guidance on Strong NovaSeq X Demand
ILMN has more than doubled off its 52-week low of $88 on elevated volume (2.1× avg).
Summary
Illumina reported Q2 2026 revenue of $1.16 billion, up 9.5% year-over-year, and raised its full-year guidance. Strong NovaSeq X demand and consumables growth drove the beat, while operating margins expanded. A new $1.5 billion buyback was also authorized.
Key Events · Earnings and Guidance · ILMN
-
Q2 Revenue and EPS Beat
Revenue of $1.16 billion grew 9.5% year-over-year, exceeding the $1.13 billion consensus. Adjusted EPS also topped estimates, driven by strong NovaSeq X instrument and consumables sales.
-
Full-Year Guidance Raised
Management increased its 2026 revenue and earnings outlook, citing sustained demand and improving operational leverage. This marks the second consecutive guidance raise.
-
Operating Margin Expansion
Year-to-date operating margin reached 20.2%, up from 18.0% a year ago, as gross margin improved to 66.2% and R&D spending declined slightly.
-
New $1.5 Billion Buyback Authorized
The board authorized an additional $1.5 billion share repurchase program in April 2026, supplementing the existing $279 million remaining under the prior program. $366 million was repurchased year-to-date.
Analysis · ILMN · Industrial Applications And Services
A clean beat-and-raise quarter underscores Illumina's momentum. Revenue of $1.16 billion grew 9.5% year-over-year, topping consensus, while adjusted EPS also exceeded expectations. Confidence in sustained demand for the NovaSeq X platform and consumables prompted management to lift the full-year revenue and earnings outlook. Operating margins expanded to 20.2% year-to-date, fueled by higher gross margins and disciplined spending. These results arrive despite headwinds from China restrictions, NIH funding uncertainty, and tariffs. Adding to shareholder returns, the board authorized a new $1.5 billion buyback, supplementing the existing program. This quarter marks a clear inflection in Illumina's post-GRAIL recovery narrative.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ILMN was trading at $205.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $31B. The 52-week trading range was $88.00 to $205.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.